ImmuCell Corporation
ICCC
$5.25
$0.255.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.41% | 17.76% | 11.16% | 52.10% | 11.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.41% | 17.76% | 11.16% | 52.10% | 11.40% |
| Cost of Revenue | -29.02% | -14.51% | -5.02% | 36.28% | 7.23% |
| Gross Profit | 49.22% | 129.00% | 46.12% | 81.46% | 25.00% |
| SG&A Expenses | 20.14% | -10.72% | 11.00% | 16.41% | 2.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.71% | -14.35% | -8.04% | 20.64% | 0.09% |
| Operating Income | 103.50% | 141.08% | 472.41% | 315.82% | 51.44% |
| Income Before Tax | 80.68% | 132.92% | 431.94% | 145.73% | 25.47% |
| Income Tax Expenses | 246.15% | 46.15% | 46.15% | 361.54% | 550.00% |
| Earnings from Continuing Operations | 80.09% | 132.77% | 430.44% | 145.15% | 25.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.09% | 132.77% | 430.44% | 145.15% | 25.35% |
| EBIT | 103.50% | 141.08% | 472.41% | 315.82% | 51.44% |
| EBITDA | 597.80% | 272.97% | 388.45% | 757.96% | 120.72% |
| EPS Basic | 82.07% | 128.35% | 385.13% | 139.16% | 29.18% |
| Normalized Basic EPS | 90.67% | 128.36% | 303.13% | 231.64% | 49.10% |
| EPS Diluted | 77.78% | 127.80% | 366.67% | 138.40% | 25.80% |
| Normalized Diluted EPS | 90.67% | 128.36% | 303.13% | 231.64% | 49.10% |
| Average Basic Shares Outstanding | 10.80% | 15.64% | 15.87% | 15.29% | 5.39% |
| Average Diluted Shares Outstanding | 10.80% | 15.64% | 15.87% | 15.29% | 5.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |